X4 Pharmaceuticals Dividendi e riacquisti

Dividendo criteri di controllo 0/6

X4 Pharmaceuticals non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-0.4%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-0.4%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di XFOR siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di XFOR siano aumentati.

Rendimento dei dividendi rispetto al mercato

X4 Pharmaceuticals Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di XFOR rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (XFOR)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	2.4%
Analista previsionale (XFOR) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di XFOR rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di XFOR rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di XFOR per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché XFOR non ha segnalato alcun pagamento.

X4 Pharmaceuticals Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

New major risk - Financial position

Price target decreased by 8.9% to US$3.68

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

CEO, President & Director notifies of intention to sell stock

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Founder notifies of intention to sell stock

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial

X4 Pharmaceuticals EPS misses by $0.44

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor

X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021